🇺🇸 FDA
Patent

US 8822218

Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

granted A61KA61K2035/124A61K2239/48

Quick answer

US patent 8822218 (Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts) held by Stem Cell & Regenerative Medicine International expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Stem Cell & Regenerative Medicine International
Grant date
Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2035/124, A61K2239/48, A61K40/15, A61K40/42